Phlexglobal
has launched its enhanced Resourcing Solutions division to offer increased flexibility for both commercial and NHS clients.
Following an internal restructure, Phlexglobal’s Resourcing Solutions division now comprises four subdivisions covering Recruitment, Insourced Services, Task Force and Clinical Support Services.
Resourcing Solutions is being led by Sarah Tucker who previously ran the company’s Task Force. Sarah commented: “Bringing together the four Resourcing Solutions enables Phlexglobal to support its clients through the provision of staff in the most flexible way. We offer a variety of costing and contractual models to our clients, to suit their current needs and constraints.”
The Recruitment subdivision focuses on permanent Clinical Trial Administrator (CTA), Document Manager, Clinical Research Associate (CRA), Project Manager and Research Nurse provision and Insourced Services provides these staff on a contract basis while still retaining all management. The Task Force team offers short term provision of highly experienced staff at a moment’s notice, to help with peaks in workload and to cover absence and longer term support comes from Clinical Support Services, either at Phlexglobal’s offices, at the client site or a combination of the two. Functional service provision of clinical trial administration will continue to be an essential part of this offering.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.